By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


MediciNova, Inc. 

4350 La Jolla Village Drive, Suite 950

San Diego  California  92122  U.S.A.
Phone: 858-373-1500 Fax: 858-373-7000



Company News
MediciNova, Inc. Announces Full Enrollment In Phase 2b Trial Of MN-166 (Ibudilast) In Progressive MS 5/7/2015 7:28:58 AM
Baseline Characteristics Of 228 Subjects Enrolled In MediciNova, Inc.'s Phase IIb Trial Of MN-166 (Ibudilast) In Progressive MS Presented At The American Academy of Neurology 67th Annual Meeting 4/23/2015 7:06:45 PM
MediciNova, Inc. Announces Positive Interim Safety Data From Clinical Trial Of MN-166 (Ibudilast) In ALS 4/21/2015 4:44:24 PM
FDA Grants Fast Track Designation For MediciNova, Inc.'s MN-001 (Tipelukast) For The Treatment Of NASH With Fibrosis 4/16/2015 8:30:17 AM
Tokyo Stock Exchange Announces New Rule Affecting Trading Of MediciNova, Inc. Stock In Japan 4/16/2015 8:00:41 AM
MediciNova, Inc. Release: MN-166 (Ibudilast) Effects In Opioid Dependence Selected For Presentation At The 77th Annual Meeting Of The College On Problems Of Drug Dependence In Phoenix, Arizona 3/3/2015 8:48:01 AM
MediciNova, Inc.'s MN-001 (Tipelukast) NASH With Advanced Fibrosis Abstract Accepted For Presentation At The American Association for Study of Liver Diseases And Industry Colloquium: Novel Targets And Therapies In Liver Disease In Durham, North Carolina 2/26/2015 7:55:14 AM
MediciNova, Inc. Provides Update On Clinical Trial Of MN-166 (Ibudilast) In ALS 2/17/2015 7:21:21 AM
MediciNova, Inc. Announces FDA Approval Of Protocol For Phase 2 Trial Of MN-001 In IPF 2/10/2015 7:37:47 AM
MediciNova, Inc. Receives Notice Of Allowance For New Patent Covering MN-001 And MN-002 For The Treatment Of NASH 2/4/2015 8:07:15 AM